Scleromyxedema secondary to hepatitis C virus and successfully treated with antiviral therapy

J A Smith; F A Kalimullah; C P Erickson; L S Peng

Scleromyxedema secondary to hepatitis C virus and successfully treated with antiviral therapy

Dermatol Online J. 2015 Sep 17;21(9):13030/qt1vt8c3vt.

Authors

J A Smith¹, F A Kalimullah, C P Erickson, L S Peng

Affiliation

¹ Oregon Health and Science University. jessasmith1986@gmail.com.

PMID: 26437283

Abstract

Scleromyxedema (SM) is a chronic and progressive fibromucinous disease with no known etiology. We report a patient with scleromyxedema associated with hepatitis C virus, successfully treated with interferon and ribavirin therapy.

Publication types

Case Reports

MeSH terms

Antiviral Agents / therapeutic use*
Drug Therapy, Combination
Female
Hepacivirus
Hepatitis C / complications
Hepatitis C / drug therapy*
Humans
Interferon-alpha / therapeutic use*
Middle Aged
Polyethylene Glycols / therapeutic use*
Recombinant Proteins / therapeutic use
Ribavirin / therapeutic use*
Scleromyxedema / drug therapy*
Scleromyxedema / pathology
Scleromyxedema / virology*

Substances

Antiviral Agents
Interferon-alpha
Recombinant Proteins
Polyethylene Glycols
Ribavirin
peginterferon alfa-2a